- BioMark (BUX) to present new cancer screening data using the LDTD-MS/MS technique at the Annual ASMS Conference on Mass Spectrometry
- This conference is taking place from June 5 to 9 at the Minneapolis Convention Center in Minneapolis, Minnesota
- It will be presenting new data on plasma metabolic biomarkers for early cancer detection arising from its collaborative research and development works
- These results illustrate how metabolomics fingerprinting has the potential to map out early biochemical changes in cancer cells
- BioMark is developing proprietary, non-invasive, and accurate liquid biopsy-based cancer diagnostic solutions
- BioMark Diagnostics Inc. (BUX) is trading at C$0.22 at close on April 26
BioMark Diagnostics (BUX) will present at the 70th Annual Conference of the American Society for Mass Spectrometry (ASMS).
This conference is taking place from June 5 to 9 at the Minneapolis Convention Center in Minneapolis, Minnesota.
It will be presenting new data on plasma metabolic biomarkers for early cancer detection arising from its collaborative research and development works performed with Québec-based Phytronix Technologies Inc.
Highlights of the study demonstrated that selected plasma metabolites could be repeatedly quantified in less than 10 seconds using the Luxon-MS/MS system allowing rapid and accurate quantification of cancer biomarkers from blood samples.
“BioMark is proud to showcase the results of its dynamic partnership with Phytronix to develop an ultra-high-throughput platform using the Azeo automated Liquid Handler and the LDTD-based Luxon-MS/MS system for broad cancer screening applications,” says Rashid Bux, CEO of BioMark.
These results illustrate how metabolomics fingerprinting has the potential to map out early biochemical changes in cancer cells and hence provides an opportunity for faster and more sensitive early diagnosis when treatment can be more effective,” added Bux.
Both BioMark and Phytronix are eager to showcase this integrated quantification technology platform later in 2022.
The American Society for Mass Spectrometry (ASMS) was formed in 1969 to promote and disseminate knowledge of mass spectrometry and allied topics. Membership includes over 8,500 scientists involved in research and development.
Members come from academic, industrial, and governmental laboratories.
Their interests include the advancement of techniques and instrumentation in mass spectrometry and fundamental research in chemistry, geology, forensics, biological sciences, and physics.
BioMark is developing proprietary, non-invasive, and accurate liquid biopsy-based cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early and cost-effectively.
The technology can also measure a response to treatment and potentially serial monitoring of cancer survivors.
BioMark Diagnostics Inc. (BUX) is trading at C$0.22 at close on April 26.